[go: up one dir, main page]

ZA201405746B - Rafamycin analogs and methods for making same - Google Patents

Rafamycin analogs and methods for making same

Info

Publication number
ZA201405746B
ZA201405746B ZA2014/05746A ZA201405746A ZA201405746B ZA 201405746 B ZA201405746 B ZA 201405746B ZA 2014/05746 A ZA2014/05746 A ZA 2014/05746A ZA 201405746 A ZA201405746 A ZA 201405746A ZA 201405746 B ZA201405746 B ZA 201405746B
Authority
ZA
South Africa
Prior art keywords
rafamycin
analogs
methods
making same
making
Prior art date
Application number
ZA2014/05746A
Inventor
Jonathon Zhong Zhao
Bing Wang
Original Assignee
Hangzzhou Zylox Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzzhou Zylox Pharma Co Ltd filed Critical Hangzzhou Zylox Pharma Co Ltd
Publication of ZA201405746B publication Critical patent/ZA201405746B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2014/05746A 2012-11-30 2014-08-04 Rafamycin analogs and methods for making same ZA201405746B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/085631 WO2014082286A1 (en) 2012-11-30 2012-11-30 Rafamycin analogs and methods for making same

Publications (1)

Publication Number Publication Date
ZA201405746B true ZA201405746B (en) 2015-11-25

Family

ID=50827071

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/05746A ZA201405746B (en) 2012-11-30 2014-08-04 Rafamycin analogs and methods for making same

Country Status (9)

Country Link
EP (1) EP2809675A4 (en)
JP (1) JP2016500112A (en)
KR (1) KR20150003156A (en)
CN (1) CN104854112A (en)
AU (1) AU2012395673A1 (en)
CA (1) CA2863243A1 (en)
SG (1) SG11201404432QA (en)
WO (1) WO2014082286A1 (en)
ZA (1) ZA201405746B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327097B (en) * 2014-10-11 2017-02-08 福建省微生物研究所 Triazole derivatives of rapamycin and application
CN104341434B (en) * 2014-10-16 2016-04-06 福建省微生物研究所 The rapamycin triazole derivatives replaced and purposes
CN104557975B (en) * 2014-12-23 2017-06-20 连云港恒运医药有限公司 The preparation method of everolimus intermediate and its degradation impurity
PL3061765T3 (en) * 2015-02-27 2018-07-31 Warszawski Uniwersytet Medyczny Protoescigenin derivative, process of its preparation, use of said compound and pharmaceutical composition comprising that compound
CN104876944B (en) * 2015-05-13 2017-11-10 普济生物科技(台州)有限公司 A kind of preparation method of everolimus
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
JP6793652B2 (en) * 2015-09-03 2020-12-02 日本化薬株式会社 Pharmaceutical composition containing rapamycin or a derivative thereof
CN105481704A (en) * 2016-01-12 2016-04-13 西安近代化学研究所 Method for synthesis and purification of bonding agent N-propargyl diethanol amine
CN107759616B (en) * 2016-08-23 2020-11-17 上海微创医疗器械(集团)有限公司 Compound and preparation method and application thereof
CN110831946B (en) 2017-04-05 2022-06-21 哈佛大学的校长及成员们 Macrocyclic compounds and their uses
CA3061907A1 (en) * 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
CN109776569A (en) * 2017-11-14 2019-05-21 上海医药工业研究院 A kind of preparation method of everolimus
CN108484637A (en) * 2018-03-13 2018-09-04 福建省微生物研究所 Target anticancer new drug X-76 salt-forming compounds and application thereof, preparation method
PE20252397A1 (en) 2018-05-01 2025-10-10 Revolution Medicines Inc C40, C28, AND C32-LINKED RAPAMYCIN ANALOGUES AS mTOR INHIBITORS
MX2020011564A (en) 2018-05-01 2021-01-29 Revolution Medicines Inc RAPAMYCIN ANALOGUES BINDED TO C26 AS MTOR INHIBITORS.
CN109776571B (en) * 2019-01-31 2021-06-11 哈药慈航制药股份有限公司 Rapamycin analogue and preparation method and application thereof
CN112057425A (en) * 2020-09-30 2020-12-11 严鹏科 Rapamycin preparation and preparation method thereof
EP4531859A1 (en) 2022-05-25 2025-04-09 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
CN115160343B (en) * 2022-06-09 2023-11-14 福建省微生物研究所 Rapamycin derivative, and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1998009972A1 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
CN1235608A (en) * 1996-09-09 1999-11-17 美国家用产品公司 Alkylated reapamycin derivatives
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
CA2863243A1 (en) 2014-06-05
CN104854112A (en) 2015-08-19
EP2809675A4 (en) 2015-08-12
SG11201404432QA (en) 2014-10-30
WO2014082286A1 (en) 2014-06-05
AU2012395673A8 (en) 2015-06-11
WO2014082286A9 (en) 2014-11-13
JP2016500112A (en) 2016-01-07
EP2809675A1 (en) 2014-12-10
AU2012395673A1 (en) 2014-08-14
KR20150003156A (en) 2015-01-08

Similar Documents

Publication Publication Date Title
ZA201405746B (en) Rafamycin analogs and methods for making same
GB201217018D0 (en) Methods
IL235512A0 (en) New methods
GB201223172D0 (en) Method
GB201212932D0 (en) Method
PL2817775T3 (en) Audience-measuring method
GB201212934D0 (en) Method
GB201213636D0 (en) Method
GB201210858D0 (en) Method
GB2507760B (en) Methods
SG11201407032WA (en) Method
GB201218570D0 (en) Method
GB201208874D0 (en) Methods
GB201202198D0 (en) Method
GB201223316D0 (en) Method
GB201204280D0 (en) Methods
GB201211393D0 (en) Method
GB201222737D0 (en) Method
GB201209689D0 (en) Methods
GB201217688D0 (en) Method
GB201214029D0 (en) method
GB201210147D0 (en) Method
GB201201332D0 (en) Method
GB201220686D0 (en) Methods
GB201208963D0 (en) Methods